Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA.

Merck unveiled encouraging Phase 3 KEYNOTE-689 trial results for KEYTRUDA at the AACR 2025 Meeting, sparking investor ...

The Delaware facility will ensure a domestic supply of biologic drugs including the cancer drug Keytruda.

Merck & Company, Inc. (MRK) to acquire SpringWorks Therapeutics, Inc. (SWTX) for $47/share in cash, creating synergies for ...

The deal, which has been in the works for months, hands the German pharmaceutical company two approved drugs for rare tumors.

We recently published a list of 10 Most Profitable Blue Chip Stocks to Buy Now. In this article, we are going to take a look ...

Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 billion to add ...

Germany's Merck KGaA agreed to acquire U.S. biopharmaceutical company SpringWorks Therapeutics for around $3.9 billion, in a bid to expand its oncology and rare disease business.

Merck KGaA has reached an agreement with SpringWorks on a $47-per-share takeover deal that values the US biotech at $3.9 ...

Companies are grappling with the impact of tariffs, leading to revised financial outlooks and consumer spending adjustments.

U.S. pharmaceutical giant Merck has warned that existing tariffs imposed by the Trump administration will cost the company an ...

With potential tariffs and other drug pricing policies on the horizon, the industry is navigating uncertain waters. | The ...